ARTV - Artiva Biotherapeutics, Inc.
IEX Last Trade
10.61
-0.130 -1.225%
Share volume: 1,360
Last Updated: Thu 26 Dec 2024 08:23:48 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$10.74
-0.13
-1.21%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.58%
1 Month
-10.24%
3 Months
-17.72%
6 Months
-8.67%
1 Year
-8.67%
2 Year
-8.67%
Key data
Stock price
$10.61
DAY RANGE
$10.60 - $10.82
52 WEEK RANGE
$10.09 - $17.31
52 WEEK CHANGE
-$8.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Fred Aslan
Region: US
Website: www.artivabio.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.artivabio.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California.
Recent news